Approximately 100 000 bronchiolitis admissions occur annually in the United States at an estimated cost of

Approximately 100 000 bronchiolitis admissions occur annually in the United States at an estimated cost of $1.73 billion.One prospective, population-based study sponsored by the Centers for Disease Control and Prevention reported the average RSV hospitalization rate was 5. children younger than 24 months of age during the 5-year period between 20.The guideline does not apply to children with immunodeficiencies, including those with HIV infection or recipients of solid organ or hematopoietic stem cell transplants.

||

Approximately 100 000 bronchiolitis admissions occur annually in the United States at an estimated cost of $1.73 billion.

One prospective, population-based study sponsored by the Centers for Disease Control and Prevention reported the average RSV hospitalization rate was 5. children younger than 24 months of age during the 5-year period between 20.

The guideline does not apply to children with immunodeficiencies, including those with HIV infection or recipients of solid organ or hematopoietic stem cell transplants.

.73 billion.

One prospective, population-based study sponsored by the Centers for Disease Control and Prevention reported the average RSV hospitalization rate was 5. children younger than 24 months of age during the 5-year period between 20.

The guideline does not apply to children with immunodeficiencies, including those with HIV infection or recipients of solid organ or hematopoietic stem cell transplants.

This guideline will not address long-term sequelae of bronchiolitis, such as recurrent wheezing or risk of asthma, which is a field with a large and distinct literature.

Bronchiolitis is a disorder commonly caused by viral lower respiratory tract infection in infants.

The current literature review encompasses the period from 2004 through May 2014.

The evidence-based approach to guideline development requires that the evidence in support of a policy be identified, appraised, and summarized and that an explicit link between evidence and recommendations be defined.

The goal of this guideline is to provide an evidence-based approach to the diagnosis, management, and prevention of bronchiolitis in children from 1 month through 23 months of age.

The guideline is intended for pediatricians, family physicians, emergency medicine specialists, hospitalists, nurse practitioners, and physician assistants who care for these children.This guideline is a revision of the clinical practice guideline, “Diagnosis and Management of Bronchiolitis,” published by the American Academy of Pediatrics in 2006.The guideline applies to children from 1 through 23 months of age. Each key action statement indicates level of evidence, benefit-harm relationship, and level of recommendation.This update of the 2006 AAP bronchiolitis guideline evaluates published evidence, including that used in the 2006 guideline as well as evidence published since 2004.Key action statements (KASs) based on that evidence are provided.Key action statements are as follows: The guideline offered recommendations ranked according to level of evidence and the benefit-harm relationship.